Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $1.1 million.

  • Harvard Bioscience's Cash from Operations rose 22874.11% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 11279.24%. This contributed to the annual value of $1.4 million for FY2024, which is 8973.48% down from last year.
  • Per Harvard Bioscience's latest filing, its Cash from Operations stood at $1.1 million for Q3 2025, which was up 22874.11% from $2.8 million recorded in Q2 2025.
  • Harvard Bioscience's Cash from Operations' 5-year high stood at $4.4 million during Q3 2023, with a 5-year trough of -$2.0 million in Q1 2022.
  • Its 5-year average for Cash from Operations is $1.3 million, with a median of $1.1 million in 2025.
  • Data for Harvard Bioscience's Cash from Operations shows a peak YoY increase of 218974.36% (in 2022) and a maximum YoY decrease of 29151.4% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Harvard Bioscience's Cash from Operations stood at $117000.0 in 2021, then surged by 2189.74% to $2.7 million in 2022, then surged by 60.62% to $4.3 million in 2023, then tumbled by 59.91% to $1.7 million in 2024, then crashed by 37.16% to $1.1 million in 2025.
  • Its Cash from Operations stands at $1.1 million for Q3 2025, versus $2.8 million for Q2 2025 and $3.0 million for Q1 2025.